immunotherapy

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker ResearchLunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL,…

4 hours ago
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate UpdatesJunshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

2 days ago
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company…

2 days ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesCheckpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28,…

3 days ago
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaOcean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative…

3 days ago
CG Oncology Reports 2024 Year End Financial Results and Provides Business UpdatesCG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) -…

3 days ago
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent…

3 days ago
Tempest Reports Year End 2024 Financial Results and  Provides Business UpdateTempest Reports Year End 2024 Financial Results and  Provides Business Update

Tempest Reports Year End 2024 Financial Results and Provides Business Update

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma…

3 days ago
INmune Bio Inc.  Announces Year End 2024 Results and Provides a Business UpdateINmune Bio Inc.  Announces Year End 2024 Results and Provides a Business Update

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune…

3 days ago